Tag: posts

Interest in Chaga mushroom supplements is surging across 2025 wellness trends, as consumers seek cleaner, science-aligned alternatives for immune support, inflammation balance, and energy recovery. With dual-extracted fruiting body sourcing and lab-tested transparency, Pilly Labs’ latest formula is gaining attention as a serious contender in the adaptogenic mushroom space—without the hype or filler.

In this 2025 GlobeNewswire release, Nutraville explores the spiritual science behind its Pineal Awakening formula — a clean-label blend of Himalayan Shilajit and synergistic botanicals gaining attention for its connection to pineal gland detox protocols, intuitive alignment, and ancient wellness systems. This educational report highlights the rising search behavior around “wealth resin,” pineal activation, and natural clarity tools.

– Increases 2025 Outlook on Solid Growth in Net Income and FFO –

Utenos Trikotažas Posts Profit in Q2, Group Results Near Break-Even

SUGAR LAND, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- CVR Energy, Inc. (NYSE: CVI, “CVR Energy” or the “Company”) today announced second quarter 2025 net loss attributable to CVR Energy stockholders of $114 million, or $1.14 per diluted share, compared to second quarter 2024 net income attributable to CVR Energy stockholders of $21 million, or 21 cents per diluted share. Adjusted loss for the second quarter of 2025 was 23 cents per diluted share, compared to adjusted earnings per diluted share of 9 cents in the second quarter of 2024. Net loss for the second quarter of 2025 was $90 million, compared to net income of $38 million in the second quarter of 2024. Second quarter 2025 EBITDA loss was $24 million, compared to second quarter 2024 EBITDA of $103 million. Adjusted EBITDA for the second quarter of 2025 was $99 million, compared to adjusted EBITDA of $87 million in the second quarter of 2024.

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI^®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.

747 Media House leads cannabis SEO and dispensary marketing in 2025. Understand why it's the top-rated cannabis marketing agency driving revenue and compliance.